Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 243-253

  Teerlink, John R ^a   Metra, Marco ^b   Zacà, Valerio ^c   Sabbah, Hani N ^d   Cotter, Gadi ^e   Gheorghiade, Mihai ^f   Cas, Livio Dei ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^e Momentum Research Inc   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute heart failure; Advanced chronic heart failure; Inotropic agents; Istaroxime; Omecamtiv mecarbil References :; Prognosis

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC MYOSIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENOXIMONE; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; MILRINONE; OMECAMTIV MECARBIL; PERHEXILINE; PIMOBENDAN; PIPERANOMETOZINE; PLACEBO; RANOLAZINE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARRHYTHMOGENESIS; CARDIOTOXICITY; CLINICAL EXAMINATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PERFUSION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PROGNOSIS; REGISTER; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION;

ACUTE DISEASE; CARDIOTONIC AGENTS; DIGOXIN; DOBUTAMINE; ETIOCHOLANOLONE; EXERCISE TEST; HEART FAILURE; HEMODYNAMICS; HOSPITALS, GROUP PRACTICE; HUMANS; HYDRAZONES; PROGNOSIS; PYRIDAZINES; QUINOLINES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TREATMENT OUTCOME; UREA; VASODILATOR AGENTS;

EID: 70449527550     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-009-9153-y     Document Type: Review

References (61)

1. LW Stevenson 2003 Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization Circulation 108 367 372 10.1161/01.CIR.0000078348.44634.BA 12876135 (Pubitemid 36899031)
2. LW Stevenson 2003 Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy Circulation 108 492 497 10.1161/01.CIR.0000078349.43742.8A 12885733 (Pubitemid 36935545)
3. JR Teerlink 2005 Overview of randomized clinical trials in acute heart failure syndromes Am J Cardiol 96 59G 67G 10.1016/j.amjcard.2005.07.022 16181824 (Pubitemid 41338075)
4. EM deGoma RH Vagelos MB Fowler EA Ashley 2006 Emerging therapies for the management of decompensated heart failure: from bench to bedside J Am Coll Cardiol 48 2397 2409 10.1016/j.jacc.2006.08.039 17174176 (Pubitemid 44881226)
5. L De Luca A Mebazaa G Filippatos JT Parissis M Böhm AA Voors M Nieminen F Zannad A Rhodes A El-Banayosy K Dickstein M Gheorghiade 2008 Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail 10 201 213 10.1016/j.ejheart.2008.01.002 18279775 (Pubitemid 351227429)
6. M Gheorghiade PS Pang 2009 Acute heart failure syndromes J Am Coll Cardiol 53 557 573 10.1016/j.jacc.2008.10.041 19215829
7. M Gheorghiade WT Abraham NM Albert BH Greenberg CM O'Connor L She WG Stough CW Yancy JB Young GC Fonarow OPTIMIZE-HF Investigators and Coordinators 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure JAMA 296 2217 2226 10.1001/jama.296.18.2217 17090768 (Pubitemid 44708052)
8. MS Nieminen D Brutsaert K Dickstein H Drexler F Follath VP Harjola M Hochadel M Komajda J Lassus JL Lopez-Sendon P Ponikowski L Tavazzi EuroHeart Survey Investigators Heart Failure Association European Society of Cardiology 2006 EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population Eur Heart J 27 2725 2736 10.1093/eurheartj/ehl193 17000631 (Pubitemid 44729876)
9. L Tavazzi AP Maggioni D Lucci G Cacciatore G Ansalone F Oliva M Porcu Italian survey on Acute Heart Failure Investigators 2006 Nationwide survey on acute heart failure in cardiology ward services in Italy Eur Heart J 27 1207 1215 10.1093/eurheartj/ehi845 16603579 (Pubitemid 43752391)
10. MS Nieminen M Böhm MR Cowie H Drexler GS Filippatos G Jondeau Y Hasin J Lopez-Sendon A Mebazaa M Metra A Rhodes K Swedberg SG Priori MA Garcia JJ Blanc A Budaj MR Cowie V Dean J Deckers EF Burgos J Lekakis B Lindahl G Mazzotta J Morais A Oto OA Smiseth MA Garcia K Dickstein A Albuquerque P Conthe M Crespo-Leiro R Ferrari F Follath A Gavazzi U Janssens M Komajda J Morais R Moreno M Singer S Singh M Tendera K Thygesen ESC Committe for Practice Guideline (CPG) 2005 Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology Eur Heart J 26 384 416 10.1093/eurheartj/ehi044 15681577 (Pubitemid 40283098)
11. Heart Failure Society of America 2006 Executive summary: HFSA 2006 comprehensive heart failure practice guideline J Card Fail 12 10 38 10.1016/j.cardfail.2005.12.001 (Pubitemid 43267749)
12. European Society of Cardiology Heart Failure Association of the ESC (HFA) European Society of Intensive Care Medicine (ESICM) K Dickstein A Cohen-Solal G Filippatos JJ McMurray P Ponikowski PA Poole-Wilson A Strömberg DJ van Veldhuisen D Atar AW Hoes A Keren A Mebazaa M Nieminen SG Priori K Swedberg A Vahanian J Camm R De Caterina V Dean K Dickstein G Filippatos C Funck-Brentano I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano M Tendera A Auricchio J Bax M Böhm U Corrà P Della Bella PM Elliott F Follath M Gheorghiade Y Hasin A Hernborg T Jaarsma M Komajda R Kornowski M Piepoli B Prendergast L Tavazzi JL Vachiery FW Verheugt JL Zamorano F Zannad 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 933 989 10.1016/j.ejheart.2008.08.005 18826876
13. M Jessup WT Abraham DE Casey AM Feldman GS Francis TG Ganiats MA Konstam DM Mancini PS Rahko MA Silver LW Stevenson CW Yancy 2009 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 1977 2016 10.1161/CIRCULATIONAHA.109.192064 19324967
14. CW Yancy M Lopatin LW Stevenson T De Marco GC Fonarow ADHERE Scientific Advisory Committee and Investigators 2006 Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database J Am Coll Cardiol 47 76 84 10.1016/j.jacc.2005.09.022 16386668 (Pubitemid 43005168)
15. KF Adams Jr GC Fonarow CL Emerman TH LeJemtel MR Costanzo WT Abraham RL Berkowitz M Galvao DP Horton ADHERE Scientific Advisory Committee and Investigators 2005 Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 209 216 10.1016/j.ahj.2004.08. 005 15846257 (Pubitemid 40348525)
16. A Nohria E Lewis LW Stevenson 2002 Medical management of advanced heart failure JAMA 287 628 640 10.1001/jama.287.5.628 11829703
17. A Nohria SW Tsang JC Fang EF Lewis JA Jarcho GH Mudge LW Stevenson 2003 Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure J Am Coll Cardiol 41 1797 1804 10.1016/S0735-1097(03)00309-7 12767667 (Pubitemid 36584255)
18. M Metra P Ponikowski K Dickstein JJ McMurray A Gavazzi CH Bergh AG Fraser T Jaarsma A Pitsis P Mohacsi M Böhm S Anker H Dargie D Brutsaert M Komajda Heart Failure Association of the European Society of Cardiology 2007 Advanced chronic heart failure: a position statement from the study group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 9 684 694 10.1016/j.ejheart.2007.04.003 17481947 (Pubitemid 46705572)
19. T Jaarsma JM Beattie M Ryder FH Rutten T McDonagh P Mohacsi SA Murray T Grodzicki I Bergh M Metra I Ekman C Angermann M Leventhal A Pitsis SD Anker A Gavazzi P Ponikowski K Dickstein E Delacretaz L Blue F Strasser J McMurray Advanced Heart Failure Study Group of the HFA of the ESC 2009 Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 11 433 443 10.1093/eurjhf/hfp041 19386813
20. LW Stevenson FD Pagani JB Young M Jessup L Miller RL Kormos DC Naftel K Ulisney P Desvigne-Nickens JK Kirklin 2009 INTERMACS profiles of advanced heart failure: the current picture J Heart Lung Transplant 28 535 541 10.1016/j.healun.2009.02.015 19481012
21. M Gheorghiade KF Adams JG Cleland G Cotter GM Felker GS Filippatos GC Fonarow BH Greenberg AF Hernandez S Khan M Komajda MA Konstam PP Liu AP Maggioni BM Massie JJ McMurray M Mehra M Metra J O'Connell CM O'Connor PS Pang IL Piña HN Sabbah JR Teerlink JE Udelson CW Yancy F Zannad N Stockbridge Acute Heart Failure Syndromes International Working Group 2009 Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group Am Heart J 157 957 970 10.1016/j.ahj.2009.04.010 19464405
22. WT Abraham KF Adams GC Fonarow MR Costanzo RL Berkowitz TH LeJemtel ML Cheng J Wynne ADHERE Scientific Advisory Committee and Investigators ADHERE Study Group 2005 In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 57 64 10.1016/j.jacc.2005.03.051 15992636 (Pubitemid 40905130)
23. U Elkayam G Tasissa C Binanay LW Stevenson M Gheorghiade JW Warnica JB Young BK Rayburn JG Rogers T DeMarco CV Leier 2007 Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 98 104 10.1016/j.ahj.2006.09.005 17174645 (Pubitemid 44880871)
24. S Thackray J Easthaugh N Freemantle JG Cleland 2002 The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis Eur J Heart Fail 4 515 529 10.1016/S1388-9842(02)00041-7 12167393 (Pubitemid 36564973)
25. MS Cuffe RM Califf KF Adams Jr R Benza R Bourge WS Colucci BM Massie CM O'Connor I Pina R Quigg MA Silver M Gheorghiade Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators 2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 1541 1547 10.1001/jama.287.12.1541 11911756 (Pubitemid 34269999)
26. GM Felker RL Benza AB Chandler JD Leimberger MS Cuffe RM Califf M Gheorghiade CM O'Connor OPTIME-CHF Investigators 2003 Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 997 1003 10.1016/S0735-1097(02)02968-6 12651048 (Pubitemid 36315544)
27. CM O'Connor WA Gattis BF Uretsky KF Adams Jr SE McNulty SH Grossman WJ McKenna F Zannad K Swedberg M Gheorghiade RM Califf 1999 Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 78 86 10.1016/S0002-8703(99)70250-4 10385768 (Pubitemid 29331125)
28. F Oliva R Latini A Politi L Staszewsky AP Maggioni E Nicolis F Mauri 1999 Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial Am Heart J 138 247 253 10.1016/S0002-8703(99)70108-0 10426835 (Pubitemid 29379674)
29. M Packer JR Carver RJ Rodeheffer RJ Ivanhoe R DiBianco SM Zeldis GH Hendrix WJ Bommer U Elkayam ML Kukin, et al. 1991 Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 1468 1475 1944425
30. JN Cohn SO Goldstein BH Greenberg BH Lorell RC Bourge BE Jaski SO Gottlieb F McGrew III DL DeMets BG White 1998 A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators N Engl J Med 339 1810 1816 10.1056/NEJM199812173392503 9854116 (Pubitemid 29005785)
31. J Lubsen H Just AC Hjalmarsson D La Framboise WJ Remme J Heinrich-Nols JM Dumont P Seed 1996 Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial Heart 76 3 223 231 10.1136/hrt.76.3.223 8868980
32. BD Lowes SF Shakar M Metra AM Feldman E Eichhorn JW Freytag MJ Gerber JF Liard C Hartman R Gorczynski G Evans JV Linseman J Stewart AD Robertson EB Roecker DL Demets MR Bristow 2005 Rationale and design of the enoximone clinical trials program J Card Fail 11 659 669 10.1016/j.cardfail.2005.10.013 16360960 (Pubitemid 41797494)
33. EZ Gorodeski EC Chu JR Reese MH Shishehbor E Hsich RC Starling 2009 Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure Circ Heart Fail 2 320 324 10.1161/CIRCHEARTFAILURE.108.839076 19808355
34. M Metra S Nodari A D'Aloia C Muneretto AD Robertson MR Bristow L Dei Cas 2002 Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol J Am Coll Cardiol 40 1248 1258 10.1016/S0735-1097(02)02134-4 12383572
35. AM Feldman RM Oren WT Abraham JP Boehmer PE Carson E Eichhorn EM Gilbert A Kao CV Leier BD Lowes MA Mathier FA McGrew M Metra LS Zisman SF Shakar SK Krueger AD Robertson BG White MJ Gerber GE Wold MR Bristow EMOTE Study Group 2007 Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial Am Heart J 154 861 869 10.1016/j.ahj.2007.06.044 17967591 (Pubitemid 350017711)
36. Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, Demets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; for the ESSENTIAL Investigators (2009) Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. [Epub ahead of print] PubMed PMID: 19700774
37. N Beohar AK Erdogan DC Lee HN Sabbah MJ Kern J Teerlink RO Bonow M Gheorghiade 2008 Acute heart failure syndromes and coronary perfusion J Am Coll Cardiol 52 13 16 10.1016/j.jacc.2008.03.037 18582629 (Pubitemid 351852938)
38. R Schulz J Rose C Martin OE Brodde G Heusch 1993 Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation Circulation 88 684 695 8393390
39. M Gheorghiade DJ van Veldhuisen WS Colucci 2006 Contemporary use of digoxin in the management of cardiovascular disorders Circulation 113 2556 2564 10.1161/CIRCULATIONAHA.105.560110 16735690 (Pubitemid 43948035)
40. M Gheorghiade V Hall JB Lakier S Goldstein 1989 Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure J Am Coll Cardiol 13 134 142 2562844
41. The Digitalis Investigation Group 1997 The effect of digoxin on mortality and morbidity in patients with heart failure N Engl J Med 336 525 533 10.1056/NEJM199702203360801 (Pubitemid 27085732)
42. M Gheorghiade VB Hall G Jacobsen M Alam H Rosman S Goldstein 1995 Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors Circulation 92 1801 1807 7671364
43. SS Rathore JP Curtis Y Wang MR Bristow HM Krumholz 2003 Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 871 878 10.1001/jama.289.7.871 12588271 (Pubitemid 37430346)
44. A Ahmed MW Rich TE Love DM Lloyd-Jones IB Aban WS Colucci KF Adams M Gheorghiade 2006 Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial Eur Heart J 27 178 186 10.1093/eurheartj/ehi687 16339157 (Pubitemid 43069034)
45. Digitalis Investigation Group A Ahmed F Waagstein B Pitt M White F Zannad JB Young SH Rahimtoola 2009 Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial Am J Cardiol 103 82 87 10.1016/j.amjcard.2008.06.068 19101235
46. L De Luca WS Colucci MS Nieminen BM Massie M Gheorghiade 2006 Evidence-based use of levosimendan in different clinical settings Eur Heart J 27 1908 1920 10.1093/eurheartj/ehi875 16682381 (Pubitemid 44297362)
47. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A (2008) Levosimendan: from basic science to clinical practice. Heart Fail Rev. [Epub ahead of print] PubMed PMID: 19101796
48. JG Cleland N Freemantle AP Coletta AL Clark 2006 Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 1 105 110 10.1016/j.ejheart.2005.12. 003 16387630 (Pubitemid 43012109)
49. A Mebazaa MS Nieminen M Packer A Cohen-Solal FX Kleber SJ Pocock R Thakkar RJ Padley P Põder M Kivikko SURVIVE Investigators 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 1883 1891 10.1001/jama.297.17.1883 17473298 (Pubitemid 46707842)
50. HN Sabbah M Imai D Cowart A Amato P Carminati M Gheorghiade 2007 Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure Am J Cardiol 99 41A 46A 10.1016/j.amjcard.2006.09.005 17239704 (Pubitemid 46096882)
51. Khan H, Metra M, Blair JE, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M (2009) Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. [Epub ahead of print] PubMed PMID: 19238540
52. M Gheorghiade JE Blair GS Filippatos C Macarie W Ruzyllo J Korewicki SI Bubenek-Turconi M Ceracchi M Bianchetti P Carminati D Kremastinos G Valentini HN Sabbah HORIZON-HF Investigators 2008 Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 2276 2285 10.1016/j.jacc.2008.03.015 18534276
53. SJ Shah JE Blair GS Filippatos C Macarie W Ruzyllo J Korewicki SI Bubenek-Turconi M Ceracchi M Bianchetti P Carminati D Kremastinos J Grzybowski G Valentini HN Sabbah M Gheorghiade HORIZON-HF Investigators 2009 Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial Am Heart J 157 1035 1041 10.1016/j.ahj.2009.03.007 19464414
54. Teerlink JR (2009) A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. [Epub ahead of print] PubMed PMID: 19234787
55. G Fragasso A Salerno R Spoladore G Bassanelli F Arioli A Margonato 2008 Metabolic therapy of heart failure Curr Pharm Des 14 2582 2591 10.2174/138161208786071245 18991675
56. HN Sabbah MP Chandler T Mishima G Suzuki P Chaudhry O Nass BJ Biesiadecki B Blackburn A Wolff WC Stanley 2002 Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure J Card Fail 8 416 422 10.1054/jcaf.2002.129232 12528095 (Pubitemid 36055744)
57. S Rastogi VG Sharov S Mishra RC Gupta B Blackburn L Belardinelli WC Stanley HN Sabbah 2008 Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure Am J Physiol Heart Circ Physiol 295 H2149 H2155 10.1152/ajpheart.00728.2008 18820026
58. H Tuunanen E Engblom A Naum K Någren M Scheinin B Hesse KE Juhani Airaksinen P Nuutila P Iozzo H Ukkonen LH Opie J Knuuti 2008 Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy Circulation 118 1250 1258 10.1161/CIRCULATIONAHA.108.778019 18765391
59. TT Phan GN Shivu A Choudhury K Abozguia C Davies U Naidoo I Ahmed Z Yousef J Horowitz M Frenneaux 2009 Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope Eur J Heart Fail 11 881 886 10.1093/eurjhf/hfp106 19656806
60. RJ Hajjar K Zsebo L Deckelbaum C Thompson J Rudy A Yaroshinsky H Ly Y Kawase K Wagner K Borow B Jaski B London B Greenberg DF Pauly R Patten R Starling D Mancini M Jessup 2008 Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure J Card Fail 14 355 367 10.1016/j.cardfail.2008.02.005 18514926 (Pubitemid 351756538)
61. BE Jaski ML Jessup DM Mancini TP Cappola DF Pauly B Greenberg K Borow H Dittrich KM Zsebo RJ Hajjar Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators 2009 Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial J Card Fail 15 171 181 10.1016/j.cardfail.2009.01.013 19327618